Replicative senescence is an irreversible cell cycle arrest that limits the proliferation of damaged cells and may be an important tumor suppression mechanism in vivo. This process is regulated at critical steps by the tumor suppressor p53. To identify genes that may regulate the senescence process, we performed cDNA microarray analysis of gene expression in senescent, young proliferating, and hTERT-immortalized primary human fibroblasts. The histone methyltransferase (HMTase), EZH2, was specifically downregulated in senescent cells. Activated p53 suppressed EZH2 gene expression through repression of the EZH2 gene promoter. This activity of p53 requires intact p53 transactivation and DNA binding domains. Furthermore, the repression of EZH2 promoter by p53 is dependent on p53 transcriptional target p21
Introduction
Normal somatic cells have a limited capacity for division in culture and eventually enter a state of irreversible proliferative arrest termed replicative senescence (Hayflick, 1965; Campisi, 1996) . For example, human primary fibroblasts enter replicative senescence after 50-70 population doublings (PDLs) when passaged in vitro. It has been suggested that progressive telomere shortening and the consequent dysfunctional telomere structure lead to replicative senescence (Blackburn, 2001; Karlseder et al., 2002) . Telomere erosion or disruption of telomere structure presumably generates a DNA damage signal, which activates p53 and the RB pathway at multiple levels (Bringold and Serrano, 2000; Itahana et al., 2001) . Abrogation of p53 function is sufficient to extend the replicative lifespan of human primary cells (Hara et al., 1991; Shay et al., 1993; Bond et al., 1994; Maclean et al., 1994) . In addition, activation of p53 induces premature senescence and plays a role in the generation of early aging-associated phenotypes in mice (Sharpless and DePinho, 2002; Tyner et al., 2002) . Normal human somatic cells lack the activity of the telomere lengthening enzyme telomerase (Greider and Blackburn, 1987; Kim et al., 1994) . Therefore, expression of the catalytic subunit of telomerase (hTERT), which prevents telomere shortening, is sufficient to immortalize several types of primary cells in vitro under the appropriate conditions (Bodnar et al., 1998; Vaziri and Benchimol, 1998) .
Many cell fate decisions are made at the transcriptional level in response to developmental cues. Dysregulation of the transcriptional 'memory' maintenance system can lead to disastrous consequences, ranging from developmental defects to cancer (Francis and Kingston, 2001; Jacobs and van Lohuizen, 2002) . Maintenance of these states is achieved by mechanistically distinct factors. Two groups of proteins have been implicated in maintaining chromatin structure; these include the trithorax group (TrxG) proteins and the polycomb group (PcG) proteins (Mahmoudi and Verrijzer, 2001; Simon and Tamkun, 2002) . The expression of PcG proteins is tightly regulated during normal cell proliferation and differentiation. In contrast, deregulated PcG expression has been found in several aggressive human cancers (Raaphorst et al., 2000a; van Kemenade et al., 2001; Jacobs and van Lohuizen, 2002; Kleer et al., 2003) .
The PcG protein, EZH2, a human homolog of the Drosophila PcG protein, E(Z), associates with EED and other proteins to form a complex, implicated in chromosome remodeling (Jones et al., 1998; Sewalt et al., 1998) . The EZH2-EED complex methylates in vitro lysine 9 and/or lysine 27 of histone H3 (Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002) . In general, methylation of the histone H3 N-terminal tail causes stable changes in chromatin that define the status of gene expression (Strahl and Allis, 2000; Kouzarides, 2002) . Besides its role in chromatin remodeling, EZH2 is also involved in cell proliferation. The EZH2 mouse homologue was identified through an interaction with the gene product of the proto-oncogene Vav, which is required as a signaling molecule for stimulated lymphocyte proliferation (Tarakhovsky et al., 1995; Hobert et al., 1996) . EZH2 expression is rapidly upregulated in hematopoietic cells upon mitogen stimulation. In addition, the transition of resting mantle B cells to proliferating follicular centroblasts coincides with the appearance of both EZH2 and EED expression (Raaphorst et al., 2000b) . Furthermore, downregulation of EZH2 protein expression was shown to retard cell proliferation in some tumor cells (Fukuyama et al., 2000; Jacobs and van Lohuizen, 2002) .
The tumor suppressor p53 coordinates the cellular response to various kinds of stress, such as genotoxic stress, hypoxia, oncogene activation, telomere shortening, and others (Giaccia and Kastan, 1998; Michael and Oren, 2002; Vousden and Lu, 2002) , to induce different responses including apoptosis, cell cycle arrest, differentiation, accelerated DNA repair, and senescence (Almog and Rotter, 1997; Itahana et al., 2001; Vousden and Lu, 2002) . Replicative senescence maintains cells in a state of irreversible growth arrest and has been suggested to suppress tumorigenesis (Yeager et al., 1998; Itahana et al., 2001; Campisi, 2003) . Our previous study indicated that p53 in young cells is more sensitive to DNA damage than that in senescent cells. Subsequently, the death pathway in senescent human fibroblasts is changed from apoptosis to necrosis in response to genotoxic stresses (Seluanov et al., 2001) . In order to decipher the molecular mechanism leading to such a physiological variation in senescence, we compared the gene expression patterns in near-senescent, young proliferating, and hTERT-immortalized WI-38 fibroblasts by Affymetrix Genechips. In this study, we show that the histone methyltransferase (HMTase), EZH2 is downregulated in senescent cells, and that this downregulation is associated with p53 activation. These observations suggested further experiments to elucidate the relationship between EZH2 and p53. We demonstrate here that activated p53 downregulates EZH2 gene expression through p53-mediated repression of the EZH2 gene promoter. Knockdown of EZH2 expression retards cell proliferation and induces G2/M arrest. We propose that p53 regulates the G2/M checkpoint through repression of EZH2 expression.
Results

Downregulation of HMTase EZH2 in senescent cells
In our previous studies, we demonstrated that the death pathway in senescent human fibroblasts in response to genotoxic stresses is altered relative to that in young fibroblasts (Seluanov et al., 2001) . The tumor suppressor p53 in young cells is more sensitive to DNA damage than in senescent cells. Although the basal p53 protein level does not appear to increase in senescent cells, the DNA binding activity and transcription activity of p53 is stimulated during the entry of cells into senescence (Afshari et al., 1993; Atadja et al., 1995) . In order to elucidate the molecular mechanisms leading to this change, we decided to compare the gene expression patterns in senescent, young proliferating, and hTERTimmortalized cells.
During serial cultivation of WI-38 human fibroblasts, a major population of cells exhibited markers of senescence including cellular enlargement, positive staining for b-galactosidase at pH 6.0 (Figure 1a , middle panel, passage 29 (p29), PDLs 50-55), and reduced DNA replication (data not shown). As expected, hTERT-immortalized cells, in which hTERT expression was confirmed by telomerase activity assay (Figure 1b) and by RT-PCR (Figure 1c) , maintained the young morphology and lacked positive staining for b-galactosidase (pH 6.0) even in late passage cells (Figure 1a right panel, passage 31 (T31), PDLs 75-80). Total RNA samples from WI-38 young (passage 21 (p21), PDLs 35-40), near-senescent (p29), and hTERT-immortalized (T31) cells were extracted and subjected to Affymetrix Genechips to analyse the specific and unique patterns of gene expression. A list of genes that were specifically either upregulated or downregulated in senescent cells was obtained (data not shown, will publish separately). In the present study, we focus on the HMTase EZH2 that was significantly downregulated in senescent cells.
To confirm the downregulation of the EZH2 gene expression in senescent cells obtained by Affymetrix Genechips, we performed semiquantitative RT-PCR analysis of EZH2 expression in young, near-senescent, and hTERT-immortalized cells. As shown in Figure 1c , EZH2 mRNA level was significantly lower in nearsenescent cells (p29) than that in young cells (p21). EZH2 mRNA level in hTERT-immortalized cells (T31) was similar to that in young cells. Quantitative real-time RT-PCR indicated that the level of EZH2 mRNA in near-senescent cells was about threefold lower than in their young or hTERT-immortalized counterparts (Figure 1d) . Interestingly, the PcG protein Bmi-1, a component of polycom repression complex 1 (PRC1) complex that was reported to be reduced in senescent cells (Itahana et al., 2003) , did not show any change in our near-senescent cells (Figure 1c ). Bmi-1 suppresses the Ink4A/p16 gene expression, which only increases after fibroblasts have completely arrested (Stein et al., 1999) , a relatively late event. Thus, Bmi-1 levels may decline in fully senescent cells. Moreover, immunoblot analysis showed that the EZH2 protein, which mainly locates in the nucleus, was significantly decreased in senescent cells, consistent with the reduced mRNA levels (Figure 1e ). It should be noted that the lower band detected (Figure 1e, The above experiments demonstrated that EZH2 mRNA and protein are downregulated in near-senescent cells. Downregulation of EZH2 expression is associated with p53 activation in senescence. We next wished to determine whether the decline of EZH2 is p53 dependent and whether this relationship also exists in young cells. To examine these possibilities, we inactivated endogenous p53 in WI-38 young cells by overexpression of the GSE56 polypeptide, the C-terminal portion of rat p53 (a.a. 275-368), which was shown to inhibit p53 transactivation activity (Ossovskaya et al., 1996) . The expression of GSE56 induced reduction of RNA and protein expression of the p53 target gene, p21
Waf1 ( Figure   2a and d), and no obvious apoptosis (data not shown). This is in agreement with a previous report (Ossovskaya et al., 1996) that expression of GSE56 induces massive p53 protein stabilization, but completely abolishes the transactivation activity of p53. It is known that abrogation of p53 function is sufficient to extend the replicative lifespan of human primary cells (Hara et al., 1991; Shay et al., 1993; Bond et al., 1994; Maclean et al., 1994) . We therefore tested whether GSE56-infected WI-38 cells exhibited prolonged growth. As expected, WI-38 GSE56 cells grew much more rapidly than control cells at early passages. Before reaching senescence, GSE56 cells gained 10 more mean PDLs than their counterparts ( Figure 2b ). These results further indicate that p53 is functionally inactive in GSE56-expressing WI-38 cells.
In the following experiments, we examined EZH2 gene expression in vector control and GSE56-infected young cells as well as in senescent cells. As shown in Figure 2a , GSE56 expression did not affect EZH2 mRNA levels in young cells, suggesting that EZH2 mRNA levels are not regulated by p53 under unstressed conditions. When both GSE56 and control cells entered a senescent state, the level of EZH2 mRNA in GSE56 senescent cells was elevated relative to that in control senescent cells (Figure 2a ). Quantitative real-time PCR analysis showed that EZH2 mRNA levels in GSE56 2c). Consistent with the RNA expression pattern, EZH2 protein levels appeared to be unaffected by GSE56 expression in young cells. However, the EZH2 protein level in GSE56 senescent cells was markedly higher than that in control senescent cells ( Figure 2d ). Taken together, these observations suggest that activated p53 repressed EZH2 mRNA expression and protein synthesis during replicative senescence process. A decline of EZH2 mRNA and protein expression was also seen in GSE56 senescent cells relative to EZH2 expression in GSE56 young cells (Figure 2a and d), indicating that there is an additional p53-independent regulatory mechanism of EZH2 gene expression during senescence.
p53-dependent downregulation of HMTase EZH2 in response to genotoxic stress
To further determine the role of p53 activation in the suppression of EZH2 gene expression, we examined EZH2 expression kinetics in WI-38 young GSE56 cells as well as in vector control cells following exposure to doxorubicin. As shown in Figure 3a , EZH2 mRNA levels gradually declined following doxorubicin exposure in control cells, but did not change in the p53-inactivated GSE56 cells. In comparison, p21
Waf1 was Figure 3 Activated wild-type p53 represses EZH2 expression. (a) Semiquantitative RT-PCR analysis. Total RNA samples were extracted at the indicated times from young WI-38 fibroblasts stably infected with empty vector or GSE56, treated with doxorubicin (0.2 mg/ml). GAPDH gene expression was used as a normalization control. (b) Immunoblot analysis of p53, EZH2, MDM2, and p21 Waf1 expression. Total protein was extracted at the indicated times from young WI-38 fibroblasts stably infected with empty vector or GSE56, treated with doxorubicin (0.2 mg/ml). Antib-tubulin was used as a control for protein loading. (c) Semiquantitative RT-PCR analysis in MCF7 cells. Total RNA samples were extracted from MCF7 vector and MCF7 p53RNAi cells treated with doxorubicin (0.2 mg/ml) for the times indicated. GAPDH gene expression was used as a normalization control. (d) Immunoblot analysis of p53, EZH2, and p21
Waf1 expression in nuclear extracts of MCF7 vector and MCF7 p53RNAi cells treated with doxorubicin (0.2 mg/ml) for the times indicated. Ponceau S staining (P.S.) was used to monitor the protein loading. Waf1 expression in nuclear extracts of LNCaP and PC3 prostate cancer cells treated with doxorubicin (0.2 mg/ml). Ponceau S staining (P.S.) was used to monitor the protein loading induced following p53 activation in control cells but not in GSE56 cells (Figure 3a) . Furthermore, Western blots showed that EZH2 protein was gradually reduced following activation of p53 by doxorubicin, but not altered in the p53-inactivated GSE56 cells ( Figure 3b ). As expected, following exposure to doxorubicin, p53 protein accumulated and became activated, which induced its target genes Mdm2 and p21 Waf1 protein expression in control cells but not in GSE56 cells (Figure 3b ). We also observed a similar p53-dependent repression of the EZH2 gene by another DNA damage agent, cisplatin (data not shown). These data indicate that EZH2 expression is repressed in a p53-dependent manner during genotoxic stress.
To determine that the repression of EZH2 gene is specifically dependent on p53 activation following genotoxic stress, and not due to possible gain of function by the GSE56 polypeptide, we examined EZH2 gene expression in MCF7 (wild-type p53) vector control and p53RNAi cells following doxorubicin treatment. It was shown that stably expressed small interfering RNAs (siRNAs), which specifically targeted p53, abolish endogenous p53 expression in MCF7 p53RNAi cells (Brummelkamp et al., 2002b) . We extracted RNA from MCF7 p53RNAi and control cells following doxorubicin treatment and examined gene expression by semiquantitative RT-PCR. As expected, EZH2 mRNA gradually declined in MCF7 control cells following doxorubicin exposure. There was no obvious alteration of EZH2 gene expression in MCF7 p53RNAi cells (Figure 3c ). Similarly, EZH2 protein expression was gradually reduced in MCF7 control cells following activation of p53 by doxorubicin, but did not change in MCF7 p53RNAi cells (Figure 3d ). In agreement with previous reports, the specific siRNAs eliminated p53 protein accumulation and thus almost completely abolished the p53 target gene p21
Waf1 induction in MCF7 p53RNAi cells following doxorubicin treatment (Figure 3c and d ). These results demonstrate that the repression of EZH2 gene is specifically dependent on activated p53 under stress conditions.
We also tested the p53-dependent repression of EZH2 gene in additional cell types. It was reported that EZH2 is overexpressed in prostate cancer and may be involved in the progression of this tumor (Jacobs and van Lohuizen, 2002; Rhodes et al., 2003) . We tested the p53-EZH2 relationship in androgen-dependent LNCaP prostate cancer cells, which express wild-type p53, and in the metastatic PC3 prostate cancer cells, which are p53-null. Following doxorubicin treatment, EZH2 mRNA gradually declined about twofold in LNCaP cells. However, EZH2 mRNA was slightly induced in the p53-negative PC3 cells (Figure 3e ). Additionally, the basal level of EZH2 mRNA in PC3 cells was approximately fourfold higher than that in LNCaP cells. In agreement with the mRNA expression patterns, EZH2 protein expression was gradually downregulated in LNCaP cells following p53 activation by doxorubicin; EZH2 protein was overexpressed in PC3 cells but was not affected by doxorubicin (Figure 3f) . As a positive control of p53 activity, p21
Waf1 mRNA was dramatically induced in LNCaP p53 wild-type cells, but did not change in p53-null PC3 cells (Figure 3e and f) . Overall, genotoxic stress induces repression of the EZH2 gene in a p53-dependent manner and p53-mediated repression of EZH2 gene expression is evident in various cell types.
Promoter of HMTase EZH2 is repressed by activated wild-type p53 through the p53-p21 Waf1 pathway
To further elucidate the mechanism by which p53 represses the EZH2 gene, we examined whether p53 regulates the EZH2 promoter. The EZH2 promoter was amplified from À1876 to þ 7 relative to the start of the first exon, which does not contain any known p53 consensus binding site (5 et al., 1992) ). This promoter (about 1.9 kb) was ligated into a luciferase reporter vector pGL3-basic (Promega) adjacent to a luciferase reporter gene, resulting in the pGL3-EZH2 promoter reporter. To examine whether the EZH2 promoter is specifically repressed by wild-type p53, the EZH2 promoter reporter and p21
Waf1 promoter reporter were transfected into p53-null PC3 cells along with wild-type p53, various p53 mutant expression plasmids, or with pCMV vector as a control. Transfection of the same amounts of wild-type p53 and various p53 mutants into PC3 cells produced similar protein levels (Figure 4a ). The activity of EZH2 promoter was remarkably repressed by wild-type p53 in a dose-dependent manner (Figure 4c ). The 22,23 p53 mutant, which is doubly mutated in the p53 transactivation domain and was shown to be transactivation impaired (Lin et al., 1994) , did not repress EZH2 promoter activity. Additionally, neither R175H p53 nor R273H p53, two natural p53 mutants frequently mutated in cancer cells, repressed the EZH2 promoter ( Figure 4c ). As a positive control, the activity of p21 Waf1 promoter was dramatically induced by wild-type p53 in a dose-dependant manner, but not by the transcription inactive 22,23 p53 mutant nor by two other p53 natural mutants (Figure 4b ). These results indicate that the EZH2 promoter is specifically repressed by wild-type p53, and that transcription repression of EZH2 is dependent on intact p53 transactivation and core DNA binding domains.
We also examined whether the EZH2 promoter repressed by endogenous wild-type p53 in MCF7 cells. When cotransfected with the pCMVDD, which encodes the C-terminal portion of mouse p53 and inactivates wild-type p53 in a dominant negative manner (Shaulian et al., 1992) , the activity of EZH2 reporter was markedly increased (Figure 4e ), indicating that transfectioninduced stress was sufficient to activate endogenous p53. In support of this notion, the activity of the p21 Waf1 promoter reporter was decreased by addition of pCMVDD plasmid (Figure 4d ). These results indicate that the EZH2 promoter is repressed in response to endogenous p53 activation. Inactivation of endogenous p53 therefore relieves the EZH2 promoter for transcription.
To further examine whether the repression of EZH2 promoter by p53 is dependent on the p53 transcriptional RNAi-producing plasmid pSuper-Waf1 to disrupt endogenous p21
Waf1 . The activity of EZH2 reporter was markedly increased by cotransfection with pSuper-Waf1, as observed with pCMVDD ( Figure 4e ). In contrast, cotransfection with the control mouse p63 RNAi-producing plasmid pSuper-mp63 did not change the activity of EZH2 reporter (Figure 4e) , indicating that the repression of EZH2 promoter by p53 is specifically dependent on p21
Waf1 . The elevation of the cyclin-dependent kinase inhibitor p21
Waf1 generally inactivates the RB/E2F pathways. The truncated E2F-1dlTA, which lacks both the transactivation and the RB-binding domains, negates both activation of gene expression by E2F and repression by E2F/ RB complexes. When cotransfected with E2F-1dlTA, the activity of EZH2 reporter was maintained at the low level. Further inactivating endogenous p53 by pCMVDD did not rescue the activity of EZH2 promoter (Figure 4e ), indicating that E2F transcription factors are involved in the basic transcription of EZH2 promotor. These results suggest that the repression of EZH2 promoter by p53 is through p53's downstream p21
Waf1 -E2F/RB pathways.
Knockdown of EZH2 expression by RNAi retards cell proliferation and induces G2/M arrest
To examine the physiological role of p53-mediated EZH2 gene repression, we used virus-mediated RNAi to knockdown EZH2 expression in young WI-38 cells. After infection with either EZH2 RNAi plasmid, pRS-EZH2, or the pRetro-Super (pRS) empty vector and puromycin selection, EZH2 protein expression was measured. Quantification of the amounts of endogenous EZH2 protein showed a specific downregulation of protein in pRS-EZH2 cells (Figure 5a ). EZH2 RNAi did not affect p53 protein expression. We then examined the proliferation of pRS-EZH2 cells with reduced EZH2 expression. A marked inhibition of cell growth (83%) was observed in pRS-EZH2 cells (Figure 5b ), whereas the pRS vector control cells showed normal cell proliferation. The morphology of pRS-EZH2 cells was flattened and enlarged similar to senescent cells, but they did not stain for SA-b-gal activity (data not shown). We next examined the cell cycle distribution of pRS-EZH2 cell assessed by BrdU incorporation and propidium iodide (PI) staining. Flow cytometric analysis showed that pRS-EZH2 cells arrested in the G2/M phase (23.4%), similar to the level of doxorubicin (Dox)-induced G2/M arrest (23.7%) at 24 h in pRS control cells (Figure 5c ). The pRS-EZH2 cells showed less BrdU incorporation (7.6%) than pRS control cells (12.5%), consistent with their slightly increased p21 Waf1 expression (Figure 5a ). There was no obvious apoptosis in pRS-EZH2 cells as indicated by lack of sub-G1 PI staining. We also observed that EZH2 protein expression is upregulated in HT1080 fibrosarcoma cells relative to normal WI-38 fibroblasts (Figure 5d ). To test the role of EZH2 in HT1080 fibrosarcoma cells, we transfected HT1080 cells with pRS-EZH2 or pRS control plasmid. After 14 days following puromycin selection, we Figure 4 The EZH2 promoter is specifically repressed by activated wild-type p53 through p53-p21
Waf1 pathway. (a) PC3 prostate cancer cells were transiently transfected with the indicated amount of wild-type p53, or the 22,23 p53, R175H p53, or R273H p53 mutant expression plasmids. The cells were harvested after 48 h and equal amounts of protein from each cell lysate were resolved by SDS-PAGE and immunoblotted with polyclonal antibodies against p53. b-Tubulin served as a loading control. (b) PC3 cells were cotransfected with a human p21
Waf1 luciferase reporter and 10 ng each of wild-type p53, or 22,23 p53, R175H p53, or R273H p53 mutant expression plasmids. The cells were then harvested and analysed by luciferase assay for p21 Waf1 promoter activity. Values shown represent luciferase activity normalized to b-galactosidase activity and are means7s.d. of triplicate readings. All luciferase assays were performed in 24-well plates. Similar results were obtained in at least two independent experiments. PGL3 was used as a control plasmid. Empty blue-script vector and experimental conditions were normalized for DNA amount. (c) PC3 cells were cotransfected with a human EZH2 luciferase reporter and increasing amounts (2, 5, 10 ng, respectively) of wild-type p53, or 22,23 p53, R175H p53, or R273H p53 mutant expression plasmids. The cells were then harvested and analysed by luciferase assay for EZH2 promoter activity. (d) MCF7 breast carcinoma cells were cotransfected with a human p21
Waf1 luciferase reporter and the indicated pCMVDD, the human p21
Waf1 RNAi producing plasmid pSuper-WAF1, the control mouse p63 producing plasmid pSupermp63, and the truncated E2F-1dlTA expression plasmids. The cells were then harvested and analysed by luciferase assay for p21 Waf1 promoter activity. (e) MCF7 breast carcinoma cells were cotransfected with a human EZH2 luciferase reporter and the indicated plasmids as 4D. The cells were then harvested and analysed by luciferase assay for EZH2 promoter activity p53-mediated EZH2 gene repression X Tang et al observed that knockdown of EZH2 expression by RNAi significantly inhibited the colony formation in contrast to pRS-transfected cells (Figure 5e ). Overall, our data indicate that activated p53 suppresses EZH2 expression and that EZH2 protein expression is required for cell proliferation in both normal and tumor cells. Knockdown of EZH2 expression retards cell proliferation and results in G2/M phase arrest.
Discussion
Cellular senescence is thought to be an important tumor suppression mechanism in vivo (Yeager et al., 1998; Campisi, 2001) , which is regulated at critical steps by p53. We used cDNA microarrays to identify genes that may regulate the senescence process. In this study, we demonstrate that HMTase EZH2 is downregulated in senescent cells. We reveal a novel link between p53 and EZH2 by showing that activated p53 suppresses EZH2 gene expression. Wild-type p53 specifically represses the promoter of the EZH2 gene, and this repression requires its intact tranactivation and DNA binding domains. Furthermore, the repression of EZH2 promoter by p53 is dependent on p53 downstream target p21
Waf1 . In addition, disruption of EZH2 expression retards cell proliferation and induces G2/M arrest. We suggest that the suppression of EZH2 expression by p53 is the one of pathways by which p53 mediates G2/M checkpoint arrest.
In addition to the morphological changes, senescent cells undergo many alterations of gene expression. Our initial studies relied on Affymetrix Genechips analysis to compare the gene expression patterns in near-senescent, young proliferating, and hTERT-immortalized WI-38 fibroblasts. We identified downregulation of the EZH2 gene in senescent cells, which was associated with p53 activation. Expression of hTERT in normal primary cells prevents telomere shortening, diminishes the endogenous DNA damage signal to p53, and maintains EZH2 expression at the levels similar to young cells. This observation encouraged us to investigate the relationship between EZH2 and p53. Indeed, we found that the EZH2 gene maintains its expression in p53-inactivated senescent cells, suggesting that p53 represses the expression of EZH2 gene during the senescence process. Furthermore, genotoxic stress induced downregulation of EZH2 expression in a p53-dependent manner. As a transcription activator, p53 activates target genes expressions through directly binding to DNA in a sequence-specific manner . However, p53 is also able to repress transcription of various promoters (Vousden and Lu, 2002; Ho and Benchimol, 2003) . For instance, repression of Cdc2, Cyclin B1, and topoisomerase II gene expression by p53 was shown to be involved in cell cycle arrest (Wang et al., 1997; Taylor et al., 1999) . Similarly, cotransfection of cells with the EZH2 promoter and wild-type p53 leads to repression of the EZH2 promoter activity, suggesting that p53 represses EZH2 expression through its promoter. Moreover, using p53 mutants, we demonstrate that intact p53 transactivation and DNA binding domains are required for its repressive activities. This repression is dependent on its downstream transcriptional target p21
WAF1
. Disruption of p21 WAF1 abrogates the p53 repression ability on the EZH2 promoter. CDKs inhibitor p21 WAF1 negates RB/E2F pathways and the truncated mutant E2F-1dlTA abolishes the activity of EZH2 promoter, suggesting that the E2F transcription factors are involved in the basic transcription of EZH2 gene. These finding are in agreement with the recently published data that EZH2 is downstream of the Rb/E2F pathway (Bracken et al., 2003) .
We were also interested in understanding the physiological role of the p53-mediated repression of EZH2 expression. Induction of p53 by various stimulations induces apoptosis, cell cycle arrest, differentiation, accelerated DNA repair, and senescence (Almog and Rotter, 1997; Itahana et al., 2001; Vousden and Lu, 2002) . The outcome of p53 induction differs according to the function of its different target genes. To reveal the Waf1 expression in young WI-38 fibroblasts that were infected with pRetro-Super (pRS) or pRS-EZH2 and selected with puromycin (1 mg/ml) for 1 week. Anti-b-tubulin was used as a control for protein loading. (b) Growth curve of young WI-38 fibroblasts stably infected with pRS and pRS-EZH2, as assessed by cell counting at the indicated days. (c) BrdU incorporation and PI staining of young WI-38 fibroblasts stably infected with pRS and pRS-EZH2 at 6 days after replating under normal condition, and of pRS-infected cells treated with doxorubicin (0.2 mg/ml) for 24 h. (d) Immunoblot analysis of EZH2 protein in nuclear extracts of young WI-38 fibroblasts and HT1080 fibrosarcoma cells. Ponceau S staining (P.S.) was used to monitor the similar protein loading. (e) Colony formation of HT1080 fibrosarcoma cells transfected with pRS and pRS-EZH2, respectively, following 14 days selection with puromycin p53-mediated EZH2 gene repression X Tang et al role of EZH2, we utilized RNAi technology to reduce EZH2 expression. We observed that knockdown of EZH2 expression retards the cell proliferation. Cytometric analysis showed that the EZH2-depleted cells arrest at the G2/M phase, suggesting that EZH2 has a role in the G2/M checkpoint. It has been shown that several p53-dependent pathways are involved in regulation of the G2/M phase transition (Taylor and Stark, 2001) . For example, Cdc2 and Cyclin B1 repressed by p53 (Taylor et al., 1999) , p21 WAF1 , GADD45, and 14-3-3s induced by p53 (Kastan et al., 1992; el-Deiry et al., 1993; Hermeking et al., 1997) , are all involved in the G2/M cell cycle checkpoint. Inhibition of Cdc2 activity by p21 WAF1 , GADD45, or 14-3-3s results in G2 arrest (Schwartz and Rotter, 1998) . Based on the functional link we uncovered among p53, p21
WAF1 and EZH2, we suggest a novel p53-mediated G2/M cell cycle arrest pathway through the p53-dependent EZH2 repression. The PcG EZH2 protein is essential for the HMTase activity of its associated complex involving epigenetic regulation (Kouzarides, 2002) . Disruption of EZH2 expression may lead to dysregulation of gene expression, which is critical for the G2/M transition.
Much evidence indicates that the EZH2 gene is involved in human malignancy. The human EZH2 gene locus maps to a critical region in malignant myeloid disorders, indicating that the EZH2 gene is involved in the pathogenesis of 7q35-q36 aberrations in myeloid leukemia. EZH2 protein has also been found to be dysregulated in Hodgkin's disease and in B-cell nonHodgkin lymphomas (Vaziri and Benchimol, 1998; Raaphorst et al., 2000a; van Kemenade et al., 2001) . In addition, overexpression of EZH2 protein is observed in prostate and breast cancer and may be involved in the progression of this malignancy (Jacobs and van Lohuizen, 2002; Kleer et al., 2003; Rhodes et al., 2003) . In agreement with these reports, we showed that EZH2 protein is also upregulated in HT1080 fibrosarcoma cells as compared to normal WI-38 fibroblasts. Inactivation of p53 protein under unstressed conditions or p53 mutant did not alter basal EZH2 expression, suggesting that upregulation of EZH2 expression in tumor cells is not related to p53 status. Based on our observations, direct disruption of EZH2 expression or indirect repression by activation of p53 may provide a novel means to control neoplastic progression.
Covalent modification of histones, including methylation and acetylation, promotes binding of specific proteins to chromatin to alter transcription (Strahl and Allis, 2000; Kouzarides, 2002) . It was shown that the upregulated loci in senescent fibroblasts and epithelial cells exhibit physical clustering patterns, suggesting that replicative senescence is associated with alteration of chromatin structure (Zhang et al., 2003) . A recent report indicates that senescent cells accumulate a distinctive type of facultative heterochromatin (SAHF), which contains the K9M H3 protein and the HP1 and is associated with inactive transcription (Narita et al., 2003) . Here we show that HMTase EZH2 is downregulated in senescent cells, which may lead to further variation of histone modification in senescence. Therefore, the alterations in chromatin structure lead to the upregulation or downregulation of the expression of a cluster of senescence-specific genes. Based on the novel relationship we discovered between p53 and EZH2, we suggest that p53 may mediate chromatin-remodeling processes during senescence through repression of EZH2 expression.
In conclusion, we have shown that HMTase EZH2 is a novel target repressed by the p53 tumor suppressor. We propose a novel p53-mediated G2/M arrest pathway through p53-dependent EZH2 repression. In addition, as the EZH2/EED complex possesses HMTase activity and covalently modifies histones, we further suggest that p53 may be involved in the regulation of chromatin structure.
Materials and methods
Cell culture
Primary human embryonic lung fibroblasts (WI-38, ATCC) were grown in MEM supplemented with 10% fetal calf serum (FCS), 1 mM sodium pyruvate, 2 mM L-glutamine. Cells were trypsinized and seeded at cell density of 1 Â 10 5 cells/plate for young cells and at cell density of 2 Â 10 5 cells/plate for nearsenescent cells and grown for 1 week. The cumulative mean PDLs were calculated using the formula: PDLs ¼ log (cell output/cell seed)/log2. MCF7 pSuper and MCF7 p53RNAi (Brummelkamp et al., 2002a) , HT1080 (ATCC), and Phoenix cells (Clontech) were grown in DMEM supplemented with 10% FCS and 2 mM L-glutamine. LNCaP and PC3 cells were grown in RPMI medium supplemented with 10% FCS. All the cells were maintained in a humidified incubator at 371C and 5% CO 2 . Genotoxic stress was induced by the addition of doxorubicin (0.2 mg/ml) to the culture medium.
Immunoblot analysis
Immunoblot analysis was performed using standard procedures (Seluanov et al., 2001) . Briefly, cells were lysed in NP-40 buffer (50 mM Tris (pH 8.0), 120 mM NaCl, 0.5% NP-40) supplemented with protease Inhibitor cocktail (Roche) for 20 min on ice to extract total protein. Nuclear proteins were extracted as the previous described (Offer et al., 2002) . Protein concentration was determined by Bradford assay. Mouse monoclonal anti-p53 (DO-1 and 1801; kindly provided by Dr D Lane), rabbit polyclonal anti-p53 (produced in our laboratory), mouse monoclonal anti-MDM2 (4B2, 2A9, 2A10; kindly provided by Dr M Oren, Weizmann Institute of Science), rabbit polyclonal anti-p21 (C-19; Santa Cruz), rabbit polyclonal anti-EZH2 (Upstate Biochemistry), and mouse monoclonal anti-b-tubulin (Sigma) were used for immunoblotting. Horseradish peroxidase (HRP)-anti-mouse and HRP-anti-rabbit (Sigma or Amersham) was used as secondary antibodies. The signal was detected by the supersignal-enhanced chemiluminescene system (Pierce). Real-time PCR was performed using the ABI Prism 7900 sequence detection system (Perkin-Elmer, Foster City, CA, USA). Quantitation was accomplished by measuring the incorporation of the fluorescent dye, SYBR-green, into the PCR product at the end of each cycle. All PCRs were performed in duplicate, and the results were averaged. The following primer pairs were used for real-time PCR: EZH2 (5 0 GAGACTGGCGAAGAGCTGTTT and GGCATCAGC CTGGCTGTATC), GAPDH (5 0 ACCCACTCCTCCACCTT TGA and 3 0 CTGTTGCTGTAGCCAAATTCGT), p21
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(5 0 GGCAGACCAGCATGACAGATT and 3 0 GCGGATTA GGGCTTCCTCTT).
Plasmids and luciferase assays
To generate the EZH2 promoter reporter construct, the EZH2 promoter was amplified from À1876 to þ 7 relative to the start of the first exon by PCR (forward primers: 5 0 GGGCGACAG TGTGAGACTCCGTTTCTTA3 0 , reverse primer 5 0 CACTG CCTTCTGAGTCCCACCGGGTGTC3 0 ). This cloned fragment of about 1.9 kb was ligated into the pGL3-basic luciferase reporter vector (Promega), resulting in the pGL3-EZH2-1.9 promoter reporter. To generate the p21 Waf1 RNAiproducing plasmid pSuper-Waf1, the annealed oligos (5 0 gatcc ccGACCATGTGGACCTGTCACttcaagagaGTGACAGGT CCACATGGTCtttttggaaa3 0 and 5 0 agcttttccaaaaaGACCAT GTGGACCTGTCACtctcttgaaGTGACAGGTCCACATGG TCggg3 0 ) was inserted into pSuper vector (from Oligoengine). Wild-type p53 (pC53-SN3), p53-175R/H, and p53-273R/H (provided by Dr B Vogelstein, The Johns Hopkins University School of Medicine), 22, 23 p53 mutant (provided by Dr A Levine, Rockefeller University), and pCMVDD expression plasmids were all driven by the CMV immediate-early promoter. The p21 Waf1 -Luc and the mouse p63 RNAiproducing plasmid pSuper-mp63 were provided by Dr M Oren (Weizmann Institute of Science). The truncated E2F-1dlTA expression plasmid was kindly provided by Dr D Ginsberg (Weizmann Institute of Science). Transfection experiments were carried out using FuGENE-6 (Roche) according to the manufacturer's instructions.
Cells were assayed for luciferase activity by the Luciferase Reporter Assay System (Promega) using a Turner Design Model 20 luminometer. Briefly, cells were seeded in 24-well plates and cotransfected with 200 ng of pGL3-EZH2-Luciferase reporter or p21 Waf1 -Luciferase reporter, 100 ng CMV-b-gal reporter, and with other indicated plasmids using the FuGENE6 Transfection Reagent (Boehringer-Mannheim) according to the manufacturer's protocol. The total amount of DNA for transfection was kept constant by addition of pBlue-script plasmid. Cells were incubated 48 h after transfection, then rinsed twice with PBS and lysed by the Passive Cell Culture Lysis Reagent (Promega) for 15 min at room temperature. Luciferase activity of each lysate (50 ml) was determined in the presence of luciferin (Promega) and ATP (Promega) by Luminometer. The activities of the experimental reporter were normalized to the activities of the b-gal control reporter.
Retroviral constructs and infection
The RNAi-producing plasmid construction was described as previous (Brummelkamp et al., 2002a) . To generate pRS-EZH2, the annealed EZH2 oligos (5 0 gatccccGAGGTTCAG ACGAGCTGATttcaagagaATCAGCTCGTCTGAACCTCttt ttggaaa3 0 and 5 0 agcttttccaaaaaGAGGTTCAGACGAGCTG ATtctcttgaaATCTGCTCGTCTGAACCTCggg3 0 ) were ligated into pRetro-Super (pRS, from Oligoengine) vector. Ecotropic receptor retroviral construct were kindly provided by Dr D Ginsberg (Weizmann institute of Science). PLXSN-GSE56-puro was described previously (Ossovskaya et al., 1996) .
For viral infection, amphotropic or ecotropic Phoenix packaging cells were transfected with 10 mg plasmids by a standard calcium phosphate procedure. Retroviral supernatants were collected at 48 and 72 h after transfection. WI-38 cells were infected with the filtered viral supernatants in the presence of 4 mg/ml polybrene (Sigma) for 5 h and maintained in MEM medium for 24 h. Infected cells were selected with 1 mg/ml Puromycin (1 week), 400 mg/ml G418 (2 weeks), or 200 mg/ml Hygromycin (1 week).
Cell cycle analysis
Subconfluent cultures were labeled with 10 mM bromodeoxyuridine (BrdU, Sigma) for 30 min. Cell were trypsinized and collected, fixed in 70% ethanol in HBSS. For flow cytometry analysis, cells were permeabilized in 2 M HCl, 0.5% Triton X-100 solution for 30 min at room temperature, neutralized in 0.1 M Na 2 B 4 O 7 at pH 8.5. Then cells were incubated with FITC-conjugated anti-BrdU (Becton Dickinson) diluted 1 : 3 in PBS/1% BSA/0.5%Tween-20 for 1 h at room temperature. Finally, cells were resuspended in PBS buffer with in 5 mg/ml propidium iodide, 0.1 mg/ml RNAse A. Flow cytometry was performed on a Becton Dickinson flow cytometer. At least 5000 cells were analysed per sample.
Colony formation assays
A total of 3 Â 10 4 cells were seeded onto 60-mm-diameter plates 16-24 h prior to transfection. At 24 h following plasmid transfection, the medium from each plate was changed and puromycin was added at the indicated concentration. The cells were maintained for 10-14 days, with fresh medium and drug replacement every 3-4 days. The number of colonies formed per plate was determined quantitatively following staining with crystal violet. Duplicate transfections were performed for each condition tested.
Senescence-associated b-galactosidase (SA-b-Gal) staining Cells were washed in PBS and fixed with 3% formaldehyde in PBS for 15 min at room temperature. Staining for the SA-b-Gal was performed as described previously (Dimri et al., 1995) .
TRAPeze assay
Telomerase activity determinations were performed using a commercial TRAPeze kit (Intergene) according to the manufacturer's nonradioactive protocol; the cycling conditions were modified as follows: 301C 30 min, 941C 3 min, and 29 cycles of amplification: 941C for 30 s, 561C for 30 s, 721C for 30 s.
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